Yearly Archives: 2013

/2013

C2 Therapeutics Receives FDA Clearance

2017-05-16T21:29:58+00:00

C2 Therapeutics’ Receives FDA Clearance for Next Generation Cryoballoon Ablation System

Redwood City, Calif. – August 22, 2013 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus), today announced that it received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Cryoballoon Focal Ablation System.  This is the company’s second 510(k) clearance and will be working to introduce Cryoballoon ablation in the United States.  nitial Human Experience with a Novel Through-the-scope Cryoballoon Device for Mucosal Ablation …

Click here to see full release.

C2 Therapeutics Receives FDA Clearance 2017-05-16T21:29:58+00:00

West Penn Allegheny Clinical Trial Tests New Barrett’s Esophagus Treatment

2017-08-28T19:48:57+00:00

West Penn Allegheny Health System researchers are investigating whether a new ablation technology can provide safer and more effective treatment for patients with Barrett’s Esophagus, a condition associated with gastroesophageal reflux disease (GERD) that can progress to esophageal cancer if left untreated.

Click here for the full story.

West Penn Allegheny Clinical Trial Tests New Barrett’s Esophagus Treatment 2017-08-28T19:48:57+00:00

C2 Therapeutics Announces 15th Patient Enrollment in its Clinical Trial

2017-05-16T21:29:58+00:00

C2 Therapeutics, a privately held company founded to address the limitations of current Barrett’s Esophagus (BE) treatment options, today announced that it enrolled the 15th patient in its Cryoballoon Focal Ablation System international study. Additionally, 10 patients have reached the 2-month follow-up period.

Click here for full release.

C2 Therapeutics Announces 15th Patient Enrollment in its Clinical Trial 2017-05-16T21:29:58+00:00